Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Magnetic Resonance Imaging (MRI) Viability: Comparison of Myocardial Viability by Positron Emission Tomography and MRI

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Randolph E Patterson, Emory University
ClinicalTrials.gov Identifier:
NCT00166179
First received: September 13, 2005
Last updated: September 25, 2014
Last verified: September 2014

September 13, 2005
September 25, 2014
November 2003
October 2006   (final data collection date for primary outcome measure)
Magnetic Resonance Imaging (MRI) Viability: Comparison of Myocardial Viability by Positron Emission Tomography and MRI [ Time Frame: time of initial scans ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00166179 on ClinicalTrials.gov Archive Site
Compare size of regions of viable and non viable myocardium as % left ventricle by MRI vs. PET [ Time Frame: at time of initial scans ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Magnetic Resonance Imaging (MRI) Viability: Comparison of Myocardial Viability by Positron Emission Tomography and MRI
Magnetic Resonance Imaging (MRI) Viability: Comparison of Myocardial Viability by Positron Emission Tomography and MRI

The purpose of this study is to compare cardiac MRI with positron emission tomography (PET) with fluorodeoxyglucose (FDG) to determine if cardiac MRI images are as good as, or better, than PET with FDG.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Age > 25 yrs, mean + SD = 60.3 + 10.2, 83% male, are patients referred by cardiologist or cardiac surgeon for assessment of myocardial viability by PET FDG.

Coronary Artery Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
57
October 2006
October 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • PET-FDG ordered to assess myocardial viability

Exclusion Criteria:

  • Contraindicated for MRI
  • Pregnant
  • Age <25 yrs
Both
18 Years to 95 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00166179
IRB00000292, 6-56550
No
Randolph E Patterson, Emory University
Emory University
Not Provided
Principal Investigator: Randolph Patterson, MD Staff
Emory University
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP